CNC Investors Have the Opportunity to Lead the Centene Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Werte in diesem Artikel
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Centene To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Centene between December 12, 2024 and June 30, 2025and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, July 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Centene Corporation ("Centene" or the "Company") (NYSE: CNC) and reminds investors of the September 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. Investors began to question the veracity of defendants' public statements on July 1, 2025, when Centene issued a press release withdrawing 2025 guidance. Particularly, following an analysis of the 2025 Health Insurance Marketplace, Centene's overall market growth across 22 states, or 72% of the Company's marketplace membership, was lower than expected. In pertinent part, the Company stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75.
Following this news, Centene's common stock declined dramatically, from a closing market price of $56.65 per share on July 1, 2025, Centene's stock price fell to $33.78 per share on July 2, 2025, a decline of 40.4%.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Centene's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Centene Corporation class action, go to www.faruqilaw.com/CNC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cnc-investors-have-the-opportunity-to-lead-the-centene-securities-fraud-lawsuit-with-faruqi--faruqi-llp-302505184.html
SOURCE Faruqi & Faruqi, LLP
Übrigens: Centene und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Centene
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Centene
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Centene Corp.
Analysen zu Centene Corp.
Datum | Rating | Analyst | |
---|---|---|---|
20.10.2017 | Centene Outperform | BMO Capital Markets | |
05.04.2017 | Centene Buy | Deutsche Bank AG | |
08.02.2017 | Centene Overweight | Barclays Capital | |
07.02.2017 | Centene Overweight | Cantor Fitzgerald | |
20.06.2016 | Centene Overweight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
20.10.2017 | Centene Outperform | BMO Capital Markets | |
05.04.2017 | Centene Buy | Deutsche Bank AG | |
08.02.2017 | Centene Overweight | Barclays Capital | |
07.02.2017 | Centene Overweight | Cantor Fitzgerald | |
20.06.2016 | Centene Overweight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
15.06.2015 | Centene Hold | Deutsche Bank AG | |
15.06.2015 | Centene Mkt Perform | FBR Capital | |
28.04.2015 | Centene Mkt Perform | FBR Capital | |
11.02.2015 | Centene Neutral | UBS AG | |
15.12.2014 | Centene Hold | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
05.12.2006 | Update Centene Corp.: Sell | Goldman Sachs | |
12.06.2006 | Update Centene Corp.: Sell | Matrix Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Centene Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen